Download PDF
Semin Thromb Hemost
DOI: 10.1055/s-0044-1787664
Review Article

Patient Perspective on Disease Burden and Gene Therapy for Hemophilia A and B: The “Haemvolution for Patients” Italian Survey

Maria Francesca Mansueto
1   Centro Emofila e Divisione di Ematologia, Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone, Palermo, Italy
,
Sarah Bigi
2   Dipartimento di Scienze Linguistiche e Letterature Straniere, Università Cattolica del Sacro Cuore, Milan, Italy
,
Marco Follino
3   Fondazione Paracelso Onlus, Milan, Italy
,
Angelo Lupi
4   Federation of Haemophilia Associations (FedEmo), Rome, Italy
,
Antonio Coppola
5   Regional Reference Centre for Inherited Bleeding Disorders, Department of General and Specialist Medicine, University Hospital of Parma, Parma, Italy
› Author Affiliations Funding The authors are members of the board of the Haemvolution for Patients project sponsored by BioMarin. The funder had no role in the design, the conduct of the study, or the analysis of the results.
› Further Information
    Permissions and Reprints

Abstract

Hemophilia is a rare X-linked congenital bleeding disorder due to a deficiency of factor VIII (hemophilia A [HA]) or factor IX (hemophilia B [HB]). Replacement and nonreplacement treatments are available but have limitations. Gene therapy (GT) provides an effective, long-term, single-dose treatment option, now approaching clinical practice. This study aimed to understand patient perspectives on GT for HA and HB in Italy using a qualitative questionnaire distributed through Italian patient associations, addressing patient views on daily life, treatments, unmet needs, quality of life (QoL), and GT for hemophilia. In total, 141 participants had HA, and 14 had HB (severe 78.6%). Daily life was most affected by pain and/or joint function limitations (57.5% of participants), high infusion frequency (42.5%), management of breakthrough bleeding episodes (40.3%), and anxiety/fear of severe or sudden bleeding (38.8%). Despite current treatments, about half of the participants experienced three or more annual bleeding episodes. Most participants knew of GT (87.2%) and expected improvements in QoL (60.5%), reduced frequency of current treatments (53.5%), and a permanent cure (49.1%); 46.4% were unaware of its once-off dosage and 46.4% were not concerned about the costs they anticipated to be associated with GT. Although several fears were reported, 25.0% of participants were willing to undergo GT with the support of a multidisciplinary team. This survey provided valuable insight into patient perspectives on hemophilia and GT in Italy. Overall, relevant proportions of patients still experience limitations affecting their daily life. Most were positive about GT and anticipated improvements in their clinical outcomes and QoL.

Keywords

disease burden - gene therapy - hemophilia - patient awareness - patient perspective

Authors' Contributions

All the authors developed the survey, performed the statistical analysis, critically analyzed the data, and revised and approved each draft and the final manuscript for publication.


Supplementary Material



Publication History

Article published online:
18 June 2024

© 2024. Thieme. All rights reserved.

Thieme Medical Publishers
333 Seventh Avenue, New York, NY 10001, USA.

 

  • References

  • 1 Srivastava A, Santagostino E, Dougall A. et al. WFH Guidelines for the management of hemophilia, 3rd edition. Haemophilia 2020; 26 (Suppl. 06) 1-158
    CrossrefPubMedGoogle Scholar
  • 2 Peyvandi F, Garagiola I, Young G. The past and future of haemophilia: diagnosis, treatments, and its complications. Lancet 2016; 388 (10040): 187-197
    CrossrefPubMedGoogle Scholar
  • 3 Rodríguez-Merchán EC, De Pablo-Moreno JA, Liras A. Gene therapy in hemophilia: recent advances. Int J Mol Sci 2021; 22 (14) 7647
    CrossrefPubMedGoogle Scholar
  • 4 Abbonizio F, Hassan HJ, Riccioni R, Santagostino E, Arcieri R, Giampaolo A. Italian Association of Haemophilia Centres (see Appendix). New data from the Italian National Register of Congenital Coagulopathies, 2016 Annual Survey. Blood Transfus 2020; 18 (01) 58-66
    PubMedGoogle Scholar
  • 5 Rodriguez-Merchan EC. Articular bleeding in hemophilia. Cardiovasc Hematol Disord Drug Targets 2016; 16 (01) 21-24
    CrossrefPubMedGoogle Scholar
  • 6 Kempton CL, Recht M, Neff A. et al. Impact of pain and functional impairment in US adults with haemophilia: Patient-reported outcomes and musculoskeletal evaluation in the pain, functional impairment and quality of life (P-FiQ) study. Haemophilia 2018; 24 (02) 261-270
    CrossrefPubMedGoogle Scholar
  • 7 Holstein K, Klamroth R, Richards M, Carvalho M, Pérez-Garrido R, Gringeri A. European Haemophilia Therapy Standardization Board. Pain management in patients with haemophilia: a European survey. Haemophilia 2012; 18 (05) 743-752
    CrossrefPubMedGoogle Scholar
  • 8 Tagliaferri A, Franchini M, Rivolta GF, Farace S, Quintavalle G, Coppola A. ad hoc Study Group. Pain assessment and management in haemophilia: A survey among Italian patients and specialist physicians. Haemophilia 2018; 24 (05) 766-773
    CrossrefPubMedGoogle Scholar
  • 9 Berntorp E, Fischer K, Hart DP. et al. Haemophilia. Nat Rev Dis Primers 2021; 7 (01) 45
    CrossrefPubMedGoogle Scholar
  • 10 Di Minno G, Castaman G, De Cristofaro R. et al. Progress, and prospects in the therapeutic armamentarium of persons with congenital hemophilia. Defining the place for liver-directed gene therapy. Blood Rev 2023; 58: 101011
    CrossrefPubMedGoogle Scholar
  • 11 Batorova A, Boban A, Brinza M. et al. Expert opinion on current and future prophylaxis therapies aimed at improving protection for people with hemophilia A. J Med Life 2022; 15 (04) 570-578
    CrossrefPubMedGoogle Scholar
  • 12 Castaman G, Linari S. Prophylactic versus on-demand treatments for hemophilia: advantages and drawbacks. Expert Rev Hematol 2018; 11 (07) 567-576
    CrossrefPubMedGoogle Scholar
  • 13 Castaman G, Di Minno G, De Cristofaro R, Peyvandi F. The arrival of gene therapy for patients with hemophilia A. Int J Mol Sci 2022; 23 (18) 10228
    CrossrefPubMedGoogle Scholar
  • 14 Perrin GQ, Herzog RW, Markusic DM. Update on clinical gene therapy for hemophilia. Blood 2019; 133 (05) 407-414
    CrossrefPubMedGoogle Scholar
  • 15 European Medicines Agency. Roctavian (valoctocogene roxaparvovec): Summary of Product Characteristics. 2022 Accessed June 12, 2023 at: https://www.ema.europa.eu/en/documents/product-information/roctavian-epar-product-information_en.pdf
    PubMedGoogle Scholar
  • 16 Ozelo MC, Mahlangu J, Pasi KJ. et al; GENEr8-1 Trial Group. Valoctocogene roxaparvovec gene therapy for hemophilia A. N Engl J Med 2022; 386 (11) 1013-1025
    CrossrefPubMedGoogle Scholar
  • 17 Mahlangu J, Kaczmarek R, von Drygalski A. et al; GENEr8-1 Trial Group. Two-year outcomes of valoctocogene roxaparvovec therapy for hemophilia A. N Engl J Med 2023; 388 (08) 694-705
    CrossrefPubMedGoogle Scholar
  • 18 Pasi KJ, Laffan M, Rangarajan S. et al. Persistence of haemostatic response following gene therapy with valoctocogene roxaparvovec in severe haemophilia A. Haemophilia 2021; 27 (06) 947-956
    CrossrefPubMedGoogle Scholar
  • 19 Pipe SW, Leebeek FWG, Recht M. et al. Gene therapy with etranacogene dezaparvovec for hemophilia B. N Engl J Med 2023; 388 (08) 706-718
    CrossrefPubMedGoogle Scholar
  • 20 Castaman G, Carulli C, De Cristofaro R. et al. Laying the foundations for gene therapy in Italy for patients with haemophilia A: A Delphi consensus study. Haemophilia 2023; 29 (02) 435-444
    CrossrefPubMedGoogle Scholar
  • 21 Abbonizio F, Biffoni M, Arcieri R, Giampaolo A. Italian Association of Haemophilia Centers (AICE). National Registry of Congenital Coagulopathies. Report 2020. Rome: National Institute of Health, ISTISAN Reports 22/38 (in Italian); 2022. . Accessed 16 April 2024 at https://www.iss.it/-/rappporto-istisan-22/38-registro-nazionale-coagulopatie-congenite.-rapporto-2020.-francesca-abbonizio-mauro-biffoni-romano-arcieri-associazione-italiana-centri-emofilia-aice-adele-giampaolo
    Google Scholar
  • 22 Kalnins W, Schelle G, Jost K, Eberl W, Tiede A. Pain therapy in haemophilia in Germany. Patient survey (BESTH study). Hamostaseologie 2015; 35 (02) 167-173
    Article in Thieme ConnectPubMedGoogle Scholar
  • 23 Kodra Y, Cavazza M, Schieppati A. et al. The social burden and quality of life of patients with haemophilia in Italy. Blood Transfus 2014; 12 (Suppl. 03) s567-s575
    PubMedGoogle Scholar
  • 24 Banchev A, Batorova A, Faganel Kotnik B. et al; Patient Advocacy Group. A cross-national survey of people living with hemophilia: impact on daily living and patient education in Central Europe. Patient Prefer Adherence 2021; 15: 871-883
    CrossrefPubMedGoogle Scholar
  • 25 Forsyth AL, Witkop M, Lambing A. et al. Associations of quality of life, pain, and self-reported arthritis with age, employment, bleed rate, and utilization of hemophilia treatment center and health care provider services: results in adults with hemophilia in the HERO study. Patient Prefer Adherence 2015; 9: 1549-1560
    CrossrefPubMedGoogle Scholar
  • 26 Shapiro S, Makris M. Haemophilia and ageing. Br J Haematol 2019; 184 (05) 712-720
    CrossrefPubMedGoogle Scholar
  • 27 Schultz DM, Beukenhorst AL, Yimer BB. et al. Weather patterns associated with pain in chronic-pain sufferers. BAMS 2020; 101: E555-E566
    CrossrefPubMedGoogle Scholar
  • 28 Zetterberg E, Ljungkvist M, Salim M. Impact of exercise on hemophilia. Semin Thromb Hemost 2018; 44 (08) 787-795
    Article in Thieme ConnectPubMedGoogle Scholar
  • 29 Biasoli C, Baldacci E, Coppola A. et al; MEMO Study Group (Appendix I). Promoting physical activity in people with haemophilia: the MEMO (Movement for persons with haEMOphilia) expert consensus project. Blood Transfus 2022; 20 (01) 66-77
    PubMedGoogle Scholar
  • 30 Zanon E, Tagliaferri A, Pasca S. et al. Physical activity improved by adherence to prophylaxis in an Italian population of children, adolescents and adults with severe haemophilia A: the SHAPE Study. Blood Transfus 2020; 18 (02) 152-158
    PubMedGoogle Scholar
  • 31 O'Hara J, Noone D, Watt M. Relationship between bleeding episodes, health-related quality of life and direct costs in adults with severe haemophilia A: Secondary analyses from the CHESS study. Haemophilia 2022; 28 (05) e117-e120
    CrossrefPubMedGoogle Scholar
  • 32 Fischer K, Steen Carlsson K, Petrini P. et al. Intermediate-dose versus high-dose prophylaxis for severe hemophilia: comparing outcome and costs since the 1970s. Blood 2013; 122 (07) 1129-1136
    CrossrefPubMedGoogle Scholar
  • 33 Rocino A, Coppola A, Franchini M. et al; Italian Association of Haemophilia Centres (AICE) Working Party. Principles of treatment and update of recommendations for the management of haemophilia and congenital bleeding disorders in Italy. Blood Transfus 2014; 12 (04) 575-598
    PubMedGoogle Scholar
  • 34 Stromer W, Pabinger I, Ay C. et al. Pain management in hemophilia: expert recommendations. Wien Klin Wochenschr 2021; 133 (19-20): 1042-1056
    CrossrefPubMedGoogle Scholar
  • 35 Croteau SE. Evolving complexity in hemophilia management. Pediatr Clin North Am 2018; 65 (03) 407-425
    CrossrefPubMedGoogle Scholar
  • 36 Hu YF, Fang YH, Lai YR, Feng XQ, Xu SQ. Application of gene therapy in hemophilia. Curr Med Sci 2022; 42 (05) 925-931
    CrossrefPubMedGoogle Scholar
  • 37 Swire-Thompson B, Lazer D. Public health and online misinformation: challenges and recommendations. Annu Rev Public Health 2020; 41: 433-451
    CrossrefPubMedGoogle Scholar
  • 38 Cook K, Forbes SP, Adamski K, Ma JJ, Chawla A, Garrison Jr LP. Assessing the potential cost-effectiveness of a gene therapy for the treatment of hemophilia A. J Med Econ 2020; 23 (05) 501-512
    CrossrefPubMedGoogle Scholar
  • 39 Bolous NS, Chen Y, Wang H. et al. The cost-effectiveness of gene therapy for severe hemophilia B: a microsimulation study from the United States perspective. Blood 2021; 138 (18) 1677-1690
    CrossrefPubMedGoogle Scholar
  • 40 Salzman R, Cook F, Hunt T. et al. Addressing the value of gene therapy and enhancing patient access to transformative treatments. Mol Ther 2018; 26 (12) 2717-2726
    CrossrefPubMedGoogle Scholar